NEW YORK (GenomeWeb) – Australian molecular diagnostics firm TBG Biotechnology announced today that it has received approval from the China Food and Drug Administration for its HLAssure SE SBT portfolio of high-resolution human leukocyte antigen (HLA) genotyping kits for hematopoietic cell transplantation (HCT).

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.